RxDoctor Payments Data

Norris Burton, MD

Family Medicine · Tifton, GANPI 1578558805

Payments from drug & device makers

$1,819in general payments, 2019–2025

Across 110 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$593
  • Smith+Nephew$219
  • AbbVie$213
  • Integra Lifesciences Corporation$161
  • Aroa Biosurgery Incorporated$118
  • Kerecis Limited$117
  • plus $400 from 8 others

What the payments were for

  • Food & beverage$1,819100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Organogenesis Inc.34$593
Smith+Nephew18$219
AbbVie(2 entities)11$213
Integra Lifesciences Corporation12$161
Aroa Biosurgery Incorporated7$118
Kerecis Limited5$117
Melinta Therapeutics, LLC7$113
Paratek Pharmaceuticals, Inc.4$74
Hydrofera LLC3$57
Solventum Corporation2$40
Bsn Medical Inc2$40
Merck3$39
Medela LLC1$20
Cashflow Solutions, LLC1$17

How this compares

$1,819 in reported general payments places this provider in the 65th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$49,316
Medicare patients
112
Services billed
591

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Daptomycin100$104,638
ErtapenemErtapenem Sodium41$22,161
CeftriaxoneCeftriaxone Sodium58$7,454
SantylCollagenase Clostridium Hist.12$4,181
Meropenem22$3,341
Gentamicin Sulfate39$3,042
Pentoxifylline95$2,348
Doxycycline Monohydrate72$1,836
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim79$754
Cefdinir28$686
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav35$637
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip13$335
Doxycycline Hyclate18$260
Fluconazole11$138
Levofloxacin13$66

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$219$4,18112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Tifton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →